Injected vaccines work, but nasal vaccines could be even better — they induce mucosal immunity in the nose and throat, where respiratory viruses enter. The nasal spray market research study shows that the vaccination application is small but the fastest‑growing, with a CAGR above 10%. Why the excitement? Because nasal vaccines are needle‑free, painless, and easier to distribute.

What's in the pipeline? Flu vaccines, COVID boosters, and even RSV vaccines. The nasal spray market trends highlight that the fastest‑growing product type is steroid sprays, but vaccines could overtake them if clinical trials succeed.

But nasal vaccines have challenges: they're less immunogenic than injected vaccines, and they require cold chain storage. Still, the convenience factor is huge.

The bottom line: if you hate needles, nasal vaccines are coming. But don't hold your breath — regulatory approval takes time.